Welcome to our dedicated page for Acrivon Therapeutics SEC filings (Ticker: ACRV), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Acrivon Therapeutics, Inc.’s SEC filings document the formal disclosures of a Nasdaq-listed clinical-stage biotechnology company focused on precision oncology. Its 8-K reports cover results of operations, financial condition, Regulation FD presentations, pipeline updates for ACR-368 and ACR-2316, and disclosures related to its internal CLIA-certified laboratory and companion diagnostic activities.
The company’s proxy materials describe annual meeting matters, board elections, auditor ratification, executive and director governance, and stockholder voting procedures. Filing records also identify the company’s common stock registration on Nasdaq and provide exhibits that support business updates, clinical program presentations, material agreements, and risk-related public-company reporting.
Gamelin Erick reported acquisition or exercise transactions in this Form 4 filing.
Acrivon Therapeutics, Inc. reported that Chief Development Officer Erick Gamelin received an equity compensation grant in the form of restricted stock units. The award covers 38,584 shares of Common Stock at a stated price of $0.00 per share, reflecting a grant rather than a market purchase.
Each RSU represents a contingent right to receive one share of Common Stock. According to the vesting schedule, 16.67% of the RSUs will vest on November 18, 2026, with the remaining units vesting in 10 substantially equal quarterly installments, subject to his continuous service. Following this grant, Gamelin directly holds 52,992 shares of Common Stock.
Devroe Eric reported acquisition or exercise transactions in this Form 4 filing.
Acrivon Therapeutics, Inc. reported that its Chief Operating Officer, Eric Devroe, received an equity award in the form of restricted stock units. On May 18, 2026, he was granted 72,981 shares of Common Stock at no cash cost as a compensation-related award.
These RSUs represent a contingent right to receive one share of Common Stock per unit. 16.67% of the RSUs will vest on November 18, 2026, with the remaining units vesting in 10 substantially equal quarterly installments, subject to his continued service. Following this award, Devroe directly holds 146,953 shares of Common Stock.
Acrivon Therapeutics, Inc. reported equity awards to senior leaders in the form of restricted stock units (RSUs) and common stock grants coded as acquisitions. One award covers 72,706 RSUs at a grant price of $0.00 per share, and another covers 180,095 shares of Common Stock at $0.00 per share.
Each RSU represents a contingent right to receive one share of Common Stock. Of the RSUs, 16.67% are scheduled to vest on November 18, 2026, with the remaining units vesting in 10 substantially equal quarterly installments, subject to the executive’s continuous service. After these grants, one indirect holding totals 386,343 shares and one direct holding totals 2,259,046 shares, with certain shares held by each executive’s spouse and the non-holding spouse disclaiming beneficial ownership except for any pecuniary interest.
Acrivon Therapeutics Chief Accounting Officer Katharine Peterson reported a small tax-related share disposition. On the vesting of restricted stock units, 99 shares of common stock were withheld by the company at a value of $1.92 per share to cover mandatory tax withholding. After this non-market transaction, she directly holds 3,907 common shares.
Acrivon Therapeutics, Inc. Chief Legal Officer Mary Miller reported a routine tax-related share disposition. On May 14, 2026, 184 shares of common stock were withheld at $1.92 per share to cover mandatory tax obligations upon the vesting of restricted stock units. After this withholding, she directly holds 32,937 shares of Acrivon common stock. This was not an open-market sale and reflects standard tax withholding mechanics rather than a discretionary trade.
Acrivon Therapeutics Chief Development Officer Erick Gamelin reported a routine tax-related share disposition. On the vesting of restricted stock units, 404 shares of common stock were withheld by the company at $1.92 per share to satisfy mandatory tax withholding obligations. After this withholding, Gamelin directly holds 14,408 shares of Acrivon common stock.
Acrivon Therapeutics, Inc. reported that Chief Operating Officer Eric Devroe had 613 shares of Common Stock withheld on May 14, 2026 to cover mandatory tax obligations tied to the vesting of restricted stock units. The shares were valued at $1.92 per share for this tax-withholding disposition, which is an administrative mechanism rather than an open-market sale. Following this event, Devroe holds 73,972 Common Stock shares directly, indicating he retains essentially his full equity position while satisfying the required tax liability.
Acrivon Therapeutics executives reported routine tax-related share dispositions tied to restricted stock unit vesting. A total of 1,743 common shares at $1.92 were withheld by the company to satisfy mandatory tax obligations, rather than sold in the open market.
After these withholdings, one executive directly holds 2,078,951 shares and another has 313,637 shares reported as indirectly held through spousal ownership, reflecting that both retain substantial positions following the transactions.
Citadel reporting persons jointly disclose beneficial ownership of 13 shares of Acrivon Therapeutics common stock. The filing states Citadel Securities LLC and affiliated entities may be deemed to beneficially own 13 shares, constituting 0.0% of the class. The filing cites 38,744,446 Shares outstanding as of March 16, 2026 as the basis for the percentage.
The statement is a joint Schedule 13G/A signed by authorized signatories and includes attribution of shared voting and dispositive power for the 13 shares to Citadel Securities and related entities.
Acrivon Therapeutics reported a net loss of $19.0 million for the quarter ended March 31, 2026, slightly improved from $19.7 million a year earlier. Research and development expenses were $15.2 million, reflecting continued investment in lead programs ACR-368 and ACR-2316, while general and administrative costs declined to $4.7 million as stock-based compensation decreased.
Cash, cash equivalents and investments totaled $97.7 million at quarter-end, and the company subsequently raised an additional $7.3 million through its at-the-market equity program. Management believes this liquidity will fund operations into the third quarter of 2027 as it advances its precision oncology pipeline, including a registrational-intent Phase 2b trial of ACR-368 in endometrial cancer and a Phase 1/2 trial of WEE1/PKMYT1 inhibitor ACR-2316.